Charite Universitaetsmedizin Berlin KöR

The Charité Universitätsmedizin Berlin conducts extensive studies on heart‑related conditions, focusing on preventing and treating atherosclerotic cardiovascular disease and related events.

• Evaluation of novel oral anticoagulants for stroke prevention in atrial fibrillation
• Assessment of new lipid‑lowering agents to reduce major adverse cardiovascular events
• Investigation of therapies aimed at improving outcomes after acute coronary syndrome

With over 50 active trials and a multidisciplinary team of 48 investigators, the site offers patients access to cutting‑edge cardiovascular research.

In the field of hematologic malignancies, the department explores innovative immunotherapies and targeted agents for various lymphomas and leukemias.

• Combination regimens for large B‑cell lymphoma using bispecific antibodies
• CAR‑T cell therapy comparisons for mantle cell and follicular lymphoma
• Trials of venetoclax‑based treatments for newly diagnosed acute myeloid leukemia

The research platform integrates tumor immunology expertise, providing patients with access to personalized cancer treatments.

The site addresses neurodegenerative disorders, aiming to slow disease progression and improve cognitive function in conditions such as Alzheimer’s disease and Parkinson’s disease.

• Early‑stage interventions evaluating amyloid‑targeting agents for mild Alzheimer’s
• Neuroprotective drug trials measuring changes in clinical dementia rating scores
• Studies on disease‑modifying therapies for Parkinson’s disease using imaging biomarkers

This neurological portfolio supports patients with early‑onset dementia and offers hope through novel therapeutic approaches.

Research in inflammatory bowel disease focuses on achieving remission and improving quality of life for patients with Crohn’s disease and ulcerative colitis.

• Oral and biologic agents evaluated for endoscopic healing in ulcerative colitis
• Fecal microbiota transplantation trials for maintenance of remission in Crohn’s disease
• Small‑molecule inhibitors targeting inflammatory pathways in both IBD subtypes

Collaborative gastroenterology teams at the hospital enable rapid enrollment and comprehensive monitoring.

The department advances treatments for retinal disorders, including age‑related macular degeneration and geographic atrophy.

• Gene‑therapy vectors assessed for slowing progression of geographic atrophy
• Anti‑VEGF and adjunctive therapies compared for diabetic macular edema
• Imaging studies evaluating novel diagnostic markers for early AMD detection

State‑of‑the‑art ophthalmic imaging facilities support precise assessment of treatment outcomes.

Investigations target rare immune conditions, particularly hereditary angioedema, to develop safer prophylactic and acute therapies.

• Subcutaneous C1‑INH replacement evaluated in pediatric and adult HAE cohorts
• Oral kallikrein inhibitors studied for long‑term attack prevention
• Safety and pharmacokinetic profiling of novel monoclonal antibodies in HAE patients

The site’s expertise in rare disease management ensures rigorous oversight and patient‑centered care.

Research addresses chronic inflammatory spine disorders, with a focus on improving remission rates in axial spondyloarthritis.

• JAK inhibitor trials for patients unresponsive to NSAIDs
• Biologic therapies compared for achieving disease remission at 16 weeks
• Imaging biomarkers used to monitor structural progression under treatment

Multidisciplinary rheumatology teams facilitate comprehensive evaluation of therapeutic efficacy.

The facility pioneers advanced diagnostic tools, including PET/CT tracers and amyloid imaging, to enhance disease detection and monitoring.

• Comparative study of [68Ga]Ga‑PTF PET/CT versus [18F]FDG PET/CT for tumor staging
• Evaluation of amyloid PET impact on clinical decision‑making in dementia care
• Development of novel biomarkers for early identification of cardiovascular risk

Integration of cutting‑edge imaging supports both clinical trials and routine patient diagnostics across specialties.